Mary Kavalam

机构：Johnson & Johnson (United States)

发表论文 6 篇 · 总被引 185 次 · h-index 3

代表论文

• Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (2019 · Diabetologia · 被引 130)
• The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial (2020 · Diabetes Obesity and Metabolism · 被引 45)
• Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 6)
• Author response for "The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> Program and the <scp>CREDENCE</scp> trial" (2020 · 被引 1)
• FP11 Efficacy and safety of subcutaneous guselkumab induction and maintenance therapy in ulcerative colitis: phase 3 ASTRO results through week 48 (2026)
• S717 The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy (2022 · The American Journal of Gastroenterology)